Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

Also called NCT01803438

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 220 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01803438
Other papers using this trial's data
  • Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms American heart journal, 2021-12 DOI, PubMed 34508694

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Argentina, Australia, Belgium, Croatia, France, Germany, Italy, Netherlands, Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01803438. Randomized; no masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2019-10-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation
Condition
Symptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases
Intervention (Device)
cryoballoon ablation system
Intervention (Drug)
Antiarrhythmic Drugs
Lead sponsor
Medtronic Cardiac Ablation Solutions (class: industry)

Record details

Record id
cardio:ct-nct01803438
Content hash
b3fa4bce45a4ed0b120939735688dc4e20d09ab6ddb4e387d9ea5bd6b375b397